Received Feb 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | — | — |
this is the second time she has had covid since boosters in 2021; covid after vaccine administration; this is the second time she has had covid since boosters in 2021; covid after vaccine administration; CONTACT CENTER SUPPORT This is a solicited report received from a Consumer or other non HCP, Program ID. A female patient received BNT162b2 (BNT162B2), in 2021 as dose number unknow (booster), single (Batch/Lot number: unknown) for covid-19 immunization; COVID-19 vaccine (COVID-19 VACCINE), as dose number unknown, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "this is the second time she has had covid since boosters in 2021; covid after vaccine administration". Therapeutic measures were taken as a result of drug ineffective, covid-19. Additional information: The reporter requesting Copay card for Paxlovid stated that was the second time she had had covid since boosters in 2021. Adverse event submitted due to rebound after Paxlovid, Covid after vaccine administration.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product BNT162b2 to the reported events drug ineffective, covid-19 cannot be ruled out.